<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="editorial" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Chem.</journal-id>
<journal-title>Frontiers in Chemistry</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Chem.</abbrev-journal-title>
<issn pub-type="epub">2296-2646</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">1501277</article-id>
<article-id pub-id-type="doi">10.3389/fchem.2024.1501277</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Chemistry</subject>
<subj-group>
<subject>Editorial</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Editorial: Recent advances in Cancer biomarkers detection in biological samples</article-title>
<alt-title alt-title-type="left-running-head">Ortega et al.</alt-title>
<alt-title alt-title-type="right-running-head">
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fchem.2024.1501277">10.3389/fchem.2024.1501277</ext-link>
</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Ortega</surname>
<given-names>Francisco G.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2409013/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Regiart</surname>
<given-names>Mat&#xed;as D.</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Fern&#xe1;ndez-Baldo</surname>
<given-names>Mart&#xed;n A.</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2403682/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Center for Genomics and Oncology Research, Andalusian Autonomous Government of Genomics and Oncological Research (GENYO)</institution>, <addr-line>Granada</addr-line>, <country>Spain</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Universidad Nacional de San Luis</institution>, <institution>Facultad de Qu&#xed;mica, Bioqu&#xed;mica y Farmacia</institution>, <institution>Instituto de Qu&#xed;mica de San Luis, INQUISAL (UNSL - CONICET)</institution>, <addr-line>San Luis</addr-line>, <country>Argentina</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited and reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/60472/overview">Huangxian Ju</ext-link>, Nanjing University, China</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Francisco G. Ortega, <email>gabriel.ortega@genyo.es</email>; Mat&#xed;as D. Regiart, <email>mregiart@unsl.edu.ar</email>; Mart&#xed;n A. Fern&#xe1;ndez-Baldo, <email>mbaldo@unsl.edu.ar</email>
</corresp>
</author-notes>
<pub-date pub-type="epub">
<day>09</day>
<month>10</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="collection">
<year>2024</year>
</pub-date>
<volume>12</volume>
<elocation-id>1501277</elocation-id>
<history>
<date date-type="received">
<day>24</day>
<month>09</month>
<year>2024</year>
</date>
<date date-type="accepted">
<day>01</day>
<month>10</month>
<year>2024</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2024 Ortega, Regiart and Fern&#xe1;ndez-Baldo.</copyright-statement>
<copyright-year>2024</copyright-year>
<copyright-holder>Ortega, Regiart and Fern&#xe1;ndez-Baldo</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<related-article id="RA1" related-article-type="commentary-article" journal-id="Front. Chem." xlink:href="https://www.frontiersin.org/researchtopic/59240" ext-link-type="uri">Editorial on the Research Topic <article-title>Recent advances in Cancer biomarkers detection in biological samples</article-title>
</related-article>
<kwd-group>
<kwd>Cancer biomaker</kwd>
<kwd>biosensor</kwd>
<kwd>electrochemistry</kwd>
<kwd>biological samples</kwd>
<kwd>nanomaterials</kwd>
</kwd-group>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Analytical Chemistry</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<p>The identification of biomarkers in biological and clinical samples is a critical component of the emerging paradigm of personalized medicine. With the significant rise in novel targeted therapies and immunotherapies, medical professionals require accurate and reliable biomarker data to make informed decisions regarding the most appropriate treatments for individual patients. Furthermore, the discovery of new biomarkers must be supported by the development of fast, easy, and cost-effective methods to ensure their widespread application in clinical practice.</p>
<p>This Research Topic presents a Research Topic of original articles and reviews that highlight the latest advances in biomarker discovery and detection methodologies.</p>
<p>In their study, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fonc.2024.1359807">Pei et al.</ext-link> conducted a bibliometric and visualization analysis focusing on the use of extracellular vesicles as a liquid biopsy tool for diagnostic biomarkers in osteosarcoma (<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fonc.2024.1359807">Pei et al.</ext-link>). Their work sheds light on the potential of circulating as non-invasive diagnostic techniques in cancer care.</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fonc.2024.1370709">Li et al.</ext-link> offered another notable contribution by systematically evaluating the efficacy of one-step nucleic acid amplification (OSNA) for diagnosing sentinel lymph node metastasis in CK19-positive cancers. As sentinel lymph node metastasis is a critical indicator of cancer prognosis, the team conducted a bioinformatic analysis based on data from The Cancer Genome Atlas (TCGA) and the Human Protein Atlas, further underscoring the importance of this method in cancer diagnostics (<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fonc.2024.1370709">Li et al.</ext-link>).</p>
<p>Similarly, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fmed.2024.1391621">Liu et al.</ext-link> performed a systematic review and a PRISMA-compliant meta-analysis to assess the diagnostic performance of OSNA in detecting sentinel lymph node metastasis in CK19-positive breast cancer. This comprehensive analysis enhances our understanding of OSNA&#x2019;s role in cancer diagnosis and patient management (<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fmed.2024.1391621">Liu et al.</ext-link>).</p>
<p>Finally, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fchem.2024.1390050">Regiart et al.</ext-link> contributed a systematic review on the latest developments in the electrochemical detection of protein biomarkers in lung cancer. Their review, covering research published in the last 5&#xa0;years, provides valuable insights into how electrochemical methods can advance cancer biomarker detection, offering a promising avenue for clinical application of their analysis (<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fchem.2024.1390050">Regiart et al.</ext-link>).</p>
<p>We extend our sincere gratitude to all the authors and reviewers who have contributed to this Research Topic, as well as the journal&#x2019;s editorial team for their invaluable support throughout the editorial process.</p>
</body>
<back>
<sec id="s1">
<title>Author contributions</title>
<p>FGO: Writing&#x2013;original draft, Writing&#x2013;review and editing. MDR: Writing&#x2013;original draft, Writing&#x2013;review and editing. MAF-B: Writing&#x2013;original draft, Writing&#x2013;review and editing.</p>
</sec>
<sec sec-type="COI-statement" id="s2">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="disclaimer" id="s3">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
</back>
</article>